<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-044012</identifier>
<setSpec>0034-7973</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pathogenic implication of two novel mutations in familial breast cancer</dc:title>
<dc:description xml:lang="en">It is estimated that 5% to 10% of all breast cancer (BC)cases are caused by inherited mutations in the tumour suppressorgenes, BRCA1 and BRCA2. Whole gene mutationanalyses of these genes have led to the identification of pathogenicmutations and others variants known as genetic variantsof uncertain significance (USV). The pathogenicity of thesegenetic variants is unclear, and therefore their clinical relevanceis uncertain, diminishing the value of genetic test results. Theaim of the study has been to characterize the clinical significanceof two novel variants detected in a previous study of 48families from the Valencian Community analyzed in the UniversityHospital La Fe of Valencia (Spain). A range of genetic andbioinformatics analyses were performed and several biochemicalcriteria were used to establish whether the genetics variantsof study were pathogenic. These assays showed that thec.5025delT variant was a deleterious mutation and thec.8038C&gt;T variant required of complementary studies to characterizeits meaning. This work highlights the importance ofstudying the USV in order to clarify their pathogenic effect thenthis information is essential for providing efficient counsellingfor BC families</dc:description>
<dc:creator>Barragán, E</dc:creator>
<dc:creator>Segura, S</dc:creator>
<dc:creator>Lerma, E</dc:creator>
<dc:creator>Palanca, S</dc:creator>
<dc:creator>Esteban, E</dc:creator>
<dc:creator>Bolufer, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Se estima que entre el 5-10% de todos los casos de cáncerde mama (CM) son causados por mutaciones en los genessupresores de tumores BRCA1y BRCA2. El análisis mutacionalcompleto de estos genes ha permitido la identificación demutaciones patogénicas así como variantes de efecto desconocido(VED). Las VED se caracterizan porque su implicaciónpatogénica es confusa, y por lo tanto su importancia clínica esincierta, disminuyendo el valor de los resultados genéticos. Elobjetivo de este estudio ha sido caracterizar la significación clínicade dos nuevas variantes detectadas en un estudio previode 48 familias de la Comunidad Valenciana analizadas en elHospital Universitario La Fe de Valencia (España).Se han realizado análisis genéticos y bioinformáticos y se hanutilizado criterios bioquímicos para establecer si las VED sonpatogénicas. Estos análisis han determinado que la variantec.5025delT es una mutación deletérea y la variante c.8038C&gt;Tafecta a secuencias consenso, requiriéndose estudios complementariospara determinar con precisión su significado</dc:description>
<dc:source>Rev. diagn. biol;54(4): 334-336, oct.-dic. 2005. ilus, tab, graf</dc:source>
<dc:identifier>ibc-044012</dc:identifier>
<dc:title xml:lang="es">Implicación patogénica de dos nuevas mutaciones en cáncer de mama familiar</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33161</dc:subject>
<dc:subject>^d28963</dc:subject>
<dc:subject>^d33779^s22033</dc:subject>
<dc:subject>^d1968^s22053</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d9346^s22033</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d36331</dc:subject>
<dc:type>article</dc:type>
<dc:date>200512</dc:date>
</metadata>
</record>
</ibecs-document>
